Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).

作者： H. Joensuu , M. Eriksson , J. Hatrmann , K. Sundby Hall , J. Schutte

DOI: 10.1200/JCO.2011.29.15_SUPPL.LBA1

关键词: Randomized controlled trial 、 Surgery 、 Sample size determination 、 Hazard ratio 、 GiST 、 Imatinib 、 Adjuvant 、 Medicine 、 Consensus criteria

摘要: LBA1 Background: Adjuvant IM administered for 12 months (mos) after surgery improves recurrence-free survival (RFS) of patients (pts) diagnosed with operable GIST. We compared …

ascopubs.org 本地加速

sci-hub.st HTML 下载加速

参考文章(0)

Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).

来源期刊

我的账户

Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).

来源期刊

相似文章 10

我的账户